title: A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
abstract: A blinded, randomized trial compared the effects of front-loaded streptokinase with those of the conventional dose of intravenous recombinant tissue-type plasminogen activator (rt-PA) on left ventricular (LV) function after acute myocardial infarction (AMI). Thrombolytic therapy was administered in the emergency departments of 30 community hospitals in central Illinois, and subsequent studies were performed at 1 tertiary referral center. Patients aged < or = 75 years with a first AMI who could be treated within 4 hours of the onset of chest pain were randomly assigned to receive either streptokinase (375,000 IU bolus, followed by 1,125,000 IU over 1 hour) or rt-PA (10 mg bolus, followed by 50 mg in the first hour, and 20 mg/hour for the next 2 hours). All patients were treated with aspirin (325 mg) and intravenous heparin. Patients were transferred for angiography within 24 hours. During the 30-month study, 253 patients were treated with intravenous thrombolytic therapy 2.4 +/- 1.0 hour after the onset of AMI. In patients with anterior wall AMI (n = 90), global LV ejection fraction measured by angiography within 24 hours was 45 +/- 12% with rt-PA, and 39 +/- 13% with streptokinase (p < 0.03). Convalescent radionuclide angiography documented a persistent beneficial effect of rt-PA on LV regional wall contractility, but not global ejection fraction. There were no differences between rt-PA and streptokinase in preserving global or regional LV function in patients with inferior wall AMI.
authors.affiliation: Prairie Cardiovascular Center, Springfield, Illinois.
authors.forename: G J
authors.initials: GJ
authors.lastname: Taylor
authors.forename: H W
authors.initials: HW
authors.lastname: Moses
authors.forename: D
authors.initials: D
authors.lastname: Koester
authors.forename: J A
authors.initials: JA
authors.lastname: Colliver
authors.forename: R E
authors.initials: RE
authors.lastname: Katholi
authors.forename: J T
authors.initials: JT
authors.lastname: Dove
authors.forename: R C
authors.initials: RC
authors.lastname: Woodruff
authors.forename: F L
authors.initials: FL
authors.lastname: Mikell
authors.forename: L C
authors.initials: LC
authors.lastname: Becker
authors.forename: F H
authors.initials: FH
authors.lastname: Sheehan
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011446:Prospective Studies; D016037:Single-Blind Method; D013300:Streptokinase / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D013300:Streptokinase; D010959:Tissue Plasminogen Activator